Correlation between MEK signature and Ras gene alteration in advanced gastric cancer

MEK inhibitor (selumetinib) is a potent, orally active inhibitor of MAPK/ERK pathway. It is important to develop an accurate and robust method indicative of RAS pathway activity to stratify potential patients who can benefit from selumetinib treatment in gastric cancer (GC). First, we surveyed the s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Ahn, Soomin, Brant, Roz, Sharpe, Alan, Dry, Jonathan R., Hodgson, Darren R., Kilgour, Elaine, Kim, Kyung, Kim, Seung Tae, Park, Se Hoon, Kang, Won Ki, Kim, Kyoung-Mee, Lee, Jeeyun
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5746083/
https://ncbi.nlm.nih.gov/pubmed/29296181
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18182
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados